

25 January 2018



(Stock code: 0690)

Awarded the "Best Corporate Social Responsibility Hong Kong Listed Company of Golden Hong Kong Stocks Award 2017" and "Capital Entrepreneur of the Year 2017" In Recognition of the Group's Outstanding Performance in Corporate Social Responsibility and Corporate Governance

[25 January 2018 – Hong Kong] A leading integrated biopharmaceutical researcher, developer and manufacturer – **Uni-Bio Science Group Limited** ("Uni-Bio Science" or "the Group"; stock code: 0690) won the prize of the "Best Corporate Social Responsibility Hong Kong Listed Company of Golden Hong Kong Stocks Award 2017" jointly issued by Zhitong Finance and Tonghuashun Finance in recognition of the Group's philosophy of "persisting in innovations and continuously giving back to the community". In addition, **Mr. Kingsley Leung**, Chairman of Uni-Bio Science, was awarded the "Capital Entrepreneur of The Year 2017" by Capital Entrepreneur Magazine in recognition of the Group's outstanding performance in corporate governance and huge growth potential.

The "Hong Kong Stocks New Opportunities Forum and Golden Hong Kong Stocks Award 2017 Ceremony" and "Capital Entrepreneur of The Year 2017 Ceremony" were held on 18 and 25, January 2018 respectively. The aforementioned events were organized by leading financial media and with prestige professionals in finance, investment bankers as well as the management of listed companies attended. The "Best Corporate Social Responsibility Hong Kong Listed Company of Golden Hong Kong Stocks Award 2017" was selected by a committee of experts to recognize Hong Kong listed companies that are actively performing their corporate social responsibilities. And the "Capital Entrepreneur of The Year 2017" was selected by professional judges to recognize successful enterprises and entrepreneurs who have contributed to the economic development of

Hong Kong from a variety of industries.



Hong Kong Stocks New Opportunities Forum and Golden Hong Kong Stocks Award 2017 Ceremony



Mr. Kingsley Leung, Chairman of Uni-Bio Science, awarded the "Capital Entrepreneur of The Year 2017"

At the "Hong Kong Stocks New Opportunities Forum and Golden Hong Kong Stocks Award 2017 Ceremony", Mr. Kingsley Leung, Chairman of Uni-Bio Science (the third in the left of Photo 1) came to the stage and received the award on behalf of the Group. Regarding the award, Chairman Liang remarked "Uni-Bio Science has been devoting itself to developing and providing medical solutions for the treatment of various diseases in China market. As drug is highly concerned with life safety and life care, the Group's acts of providing assistance to vulnerable groups in community are in line with developing good medicines to help patients. Both are the protection and concern for life."

At the "Capital Entrepreneur of The Year 2017 Ceremony," Mr. Leung received the award on behalf of the Group and delivered a thank-you speech: "This award recognizes the great efforts made by the Group. As a fully integrated biopharmaceutical company focuses on innovative drugs, the Group has achieved substantial growth equipped with outstanding manufacturing facilities and multiple proprietary". Confident about the future, he stated, "We have already rebuilt the team with many senior management came from giant biopharmaceutical companies as well as expanded our

DLK Advisory 金通策略

commercial team to cover more provinces, through which I believe will generate considerable returns for shareholders and investors in the future."

At present, through its aggressive development plan, Uni-Bio Science has established a fully integrated biotech value chain in the field of biopharmaceuticals and has become a group enterprise integrating research and development, production and sales, as well as successfully promoted various innovative drugs in China market. The Group believes that the continuous optimization of operation and management of the products will lay a solid foundation for the Group's long-term sustainable development and internal inter-regional cooperation.

- End -

About Uni-Bio Science Group Limited

Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The research and development center located in Dongguan, PRC is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with CFDA requirements. The Group also has two GMP manufacturing bases in Beijing and Shenzhen. The Group is focused on the development of novel treatments addressing the therapeutic areas of diabetes, ophthalmology and dermatology.

Uni-Bio Science Group Limited was listed on the Main Board of the Hong Kong Stock Exchange on November 12, 2001. Stock code: 0690.

This press release is issued by DLK Advisory Limited for and on behalf of **Uni-Bio Science Group Limited**.

For further information, please contact:



DLK Advisory

Michelle Shi (michelleshi@dlkadvisory.com)
Linda Liang (lindaliang@dlkadvisory.com)
Cathy Wu (cathywu@dlkadvisory.com)

Tel: +852 2857 7101 Fax: +852 2857 7103

WeChat ID: Unibio-IR



心 創 造 新 醫 藥 LEADING GENUINE INNOVATION

促進增長 國際視野 Accelerating Growth International Execution